SAI Parenterals Limited
NSE: SAIPARENT · Pharmaceuticals · sector
₹455.65NSE close 2026-10-26
Key numbers
Market cap₹1,491 cr
Price₹455.65
52w high / low₹706 / ₹400
P/E104.5xSector median 27.9x
P/B3.0xSector median 2.9x
Book value₹149.9
Dividend yield–Sector median 0.48%
ROE2.9%Sector median 11.7%
ROCE3.8%Sector median 12.3%
OPM10.2%Sector median 14.0%
Debt / equity0.65xSector median 0.16x
EV/EBITDA36.0xSector median 18.6x
Interest cover1.6x
Current ratio1.44x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹417 cr vs borrowings ₹319 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 1.6x in the last 12 months.
- Net loss in 1 of the last 3 quarters.
- Other income was 60% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹455.65 on 2026-10-26: -35.5% from the 52-week high, +13.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹612.10 · low ₹422.70
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Revenue | 96 | 198 | 179 |
| EBITDA | -4 | 26 | 24 |
| OPM % | -3.7% | 13.2% | 13.2% |
| Other income | 3 | 3 | 4 |
| Net profit | -7 | 13 | 8 |
| EPS (₹) | -2.22 | 4.02 | 1.79 |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 381 | 381 |
| EBITDA | 39 | 39 |
| Net profit | 14 | 14 |
| EPS (₹) | 4.36 | 4.36 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 491 |
| Borrowings | 319 |
| Cash & equivalents | 417 |
| Total assets | 1,424 |
| Fixed assets | 62 |
| Capital work in progress | 212 |
| Investments | 0 |
| Receivables | 181 |
| Inventory | 172 |
| Payables | 149 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 93 |
| Cash from investing | -274 |
| Cash from financing | 596 |
| Capex | 66 |
| Free cash flow | 28 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 2.9% |
| ROCE % | 3.7% |
| Debtor days | 173 |
| Inventory days | 259 |
| Payable days | 224 |
| Cash conversion cycle (days) | 208 |
| Working capital days | 239 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 51.16% |
| FIIs | 2.85% |
| DIIs | 7.84% |
| of which Mutual funds | 0.30% |
| of which Insurance | 2.35% |
| Public (non-institutions) | 38.15% |
| Quarter | Mar 2026 | Apr 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Promoters % | 51.16% | 51.16% | 51.16% | 51.16% |
| Promoter group | % |
|---|---|
| Vijitha Gorrepati | 28.91% |
| Anil Kumar Karusala | 10.32% |
| Aruna Karusala | 7.40% |
| Kunal Kakumanu | 4.53% |
| Kamala Kakumanu | 0.00% |
| V Lakshmiswari | 0.00% |
| Karusala Sashank Mouli | 0.00% |
| Mahalakshmi Karusala | 0.00% |
| Tanivi Karusala | 0.00% |
| Bhavani Davuluri | 0.00% |
| Haritha Gorrepati | 0.00% |
| Public holders above 1% | % |
|---|---|
| Bhaskara RAO Bollineni | 4.56% |
| Samarsh Capital-samarsh Capital-fund I | 3.45% |
| Kotak Mahindra Life Insurance Company Ltd. | 2.35% |
| AIG Direct LLC | 2.12% |
| Agilis Partners LLP | 2.06% |
| Kotak Life Sciences Fund I | 1.73% |
| Nanda Govind Bhattad | 1.66% |
| Reina R Jaisinghani | 1.59% |
| Sapna Sameer Shah | 1.53% |
| India Emerging Giants Fund Limited | 1.33% |
| Pooja Lakshmi Doppalapudi | 1.33% |
13,645 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SAIPARENT | ₹1,491 cr | 104.5x | 3.0x | 2.9% | 3.8% | 10.2% | – | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SAIPARENT |
| BSE code | 544742 |
| ISIN | INE0H9F01037 |
| Face value | ₹5.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.